Ombitasvir - monotherapy

Drug Profile

Ombitasvir - monotherapy

Alternative Names: ABT-267

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Anilides; Antivirals; Aza compounds; Carbamates; Pyrrolidines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 17 Feb 2017 AbbVie has patent protection for Ombitasvir worldwide
  • 15 Mar 2016 Biomarkers information updated
  • 02 Jan 2013 AbbVie is launched following separation from Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top